Name: EdgePoint Investment Group Inc. 13F Holdings
Creator: 13F Insight

AI Analysis · Q1 2026

EdgePoint Investment Group's $14.3 billion March 2026 13F is one of the more diversified and enterprise-scale books in this filing cohort — a 37-name portfolio that generates returns through a consistent thematic preference for businesses with high customer retention, recurring revenue, and pricing power: moated consumer brands, industrial distributors, healthcare diagnostics, and market infrastructure. The headline structural fact is that the portfolio's growth from $12.2 billion to $14.3 billion across Q1 was not generated by adding new names but by the existing book appreciating while the manager selectively added to the portfolio's five highest-conviction positions. The five largest additions by value were Thermo Fisher Scientific (added $141 million via a 38.5% share-count increase to $943 million), Quest Diagnostics (added $152 million via a 35% share-count increase to $440 million), S&P Global (a new $703 million entry that is the portfolio's sole large-cap financial-market infrastructure play), Restaurant Brands International (added $296 million to $1.43 billion, now the portfolio's largest position), and RB Global (added $52 million to $845 million). At the same time, the portfolio slashed three meaningful technology names: Applied Materials was reduced by 57.3% — the largest percentage decrease in the book, removing $255 million — while Ametek was reduced by 35.8% and Ross Stores was reduced by 55.9% in a move that removed $372 million from what had been the portfolio's fifth-largest position at year-end. Dollar Tree was trimmed by a more modest 4% while share-count prices were still high. The pattern across these reductions is instructive: they are concentrated in names whose earnings are more directly exposed to short-cycle consumer spending (Ross Stores, Dollar Tree), semiconductor capex cycles (Applied Materials), and industrial end-market volatility (Ametek). The manager appears to have been taking profits on positions that had appreciated materially and redeploying into names with more durable revenue visibility. The portfolio's healthcare skew — three positions in the top ten (Thermo Fisher, Revvity, Quest Diagnostics) and Twist Bioscience further down — reflects a deliberate allocation to life-sciences tools and diagnostics, subsectors whose revenue is correlated with R&D spending and clinical-test volume rather than discretionary consumer demand. For readers tracking this portfolio as a signal of where an enterprise-scale Canadian-domiciled manager is deployed, the headline read is structural moat thesis applied at portfolio scale: the manager owns franchise consumer brands, global diagnostic networks, industrial distribution platforms, and market infrastructure monopolies — names that generate returns through pricing power and customer lock-in rather than economic cyclicality.

The portfolio's top-ten holdings alone tell the central story. Restaurant Brands International at $1.43 billion and 11.5% of assets — the portfolio's single largest position — is a quick-service restaurant franchisee and franchisor with Burger King, Tim Hortons, and Popeyes Louisiana Kitchen as its three core concepts. QSR's business model is a low-margin, high-volume, asset-light franchise model in which the parent company collects royalties and rents from franchisees; the economics of the business are sensitive to commodity costs (beef, chicken, coffee) and to consumer-spending trends in the mid-tier restaurant segment. The 16.2% increase in share count in Q1 represents a meaningful addition at a time when the quick-service restaurant sector is facing both price-sensitive consumer demand and rising input costs. The portfolio manager's decision to make RB QSR the portfolio's largest holding in a quarter when the sector is under pressure is either a bet that the QSR franchise model's pricing power will allow it to pass through cost increases, or that the market has underpriced the franchise concept relative to its long-term earnings power. Both theses are compatible with a value-investor framework.

Thermo Fisher Scientific at $943 million and Revvity at $771 million represent the portfolio's largest healthcare cluster and, taken together, constitute a compelling pair-trade on the life-sciences tools and diagnostics market. Thermo Fisher is the world's largest scientific-research-tools and laboratory-services company — a diversified scientific-instruments, research-tools, and CDMO (contract development and manufacturing organization) business whose customers include pharmaceutical companies, academic research institutions, and diagnostic laboratories. The 38.5% share-count increase deployed approximately $241 million in net new capital at a time when the broader scientific-instruments sector was under pressure from U.S. federal R&D funding uncertainty and rising Asian competition in laboratory instruments. Revvity is a more specialized life-sciences company formed from the 2023 spinoff of PerkinElmer's applied, food, and environmental businesses — a portfolio of molecular-diagnostics, applied-genomics, and food-safety testing instruments. Both companies are beneficiaries of the long-running increase in R&D spending by pharmaceutical companies and of the growing demand for diagnostic testing in both clinical and non-clinical settings. The portfolio manager is making a simultaneous pair bet on the scientific-instruments and molecular-diagnostics end markets — betting that the underlying demand drivers (pharmaceutical R&D spending, precision-medicine adoption, environmental and food-safety regulation) will generate consistent revenue growth for both companies regardless of short-term funding or regulatory noise.

Quarter at a glance — Q1 2026

Top 10 holdings

Filing history